166 related articles for article (PubMed ID: 35328630)
1. Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome.
Ciraolo E; Althoff S; Ruß J; Rosnev S; Butze M; Pühl M; Frentsch M; Bullinger L; Na IK
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328630
[TBL] [Abstract][Full Text] [Related]
2. Tumor antigen-specific CD8
Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
[TBL] [Abstract][Full Text] [Related]
3. Expression analysis of PD-1 and Tim-3 immune checkpoint receptors in patients with vitiligo; positive association with disease activity.
Rahimi A; Hossein-Nataj H; Hajheydari Z; Aryanian Z; Shayannia A; Ajami A; Asgarian-Omran H
Exp Dermatol; 2019 Jun; 28(6):674-681. PubMed ID: 31046170
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment.
Yang M; Du W; Yi L; Wu S; He C; Zhai W; Yue C; Sun R; Menk AV; Delgoffe GM; Jiang J; Lu B
Oncoimmunology; 2020; 9(1):1708064. PubMed ID: 32076578
[TBL] [Abstract][Full Text] [Related]
5. Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion.
Teagle AR; Castro-Sanchez P; Brownlie RJ; Logan N; Kapoor SS; Wright D; Salmond RJ; Zamoyska R
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056892
[TBL] [Abstract][Full Text] [Related]
6. Increased Expression of Multiple Co-Inhibitory Molecules on Malaria-Induced CD8
Brandi J; Riehn M; Hadjilaou A; Jacobs T
Front Immunol; 2022; 13():878320. PubMed ID: 35874786
[TBL] [Abstract][Full Text] [Related]
7. Immune-Checkpoint Blockade Opposes CD8
Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
[TBL] [Abstract][Full Text] [Related]
8. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
9. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8
Rezazadeh H; Astaneh M; Tehrani M; Hossein-Nataj H; Zaboli E; Shekarriz R; Asgarian-Omran H
Immunol Res; 2020 Oct; 68(5):269-279. PubMed ID: 32710227
[TBL] [Abstract][Full Text] [Related]
10.
Wei Y; Zhang Z; Xue T; Lin Z; Chen X; Tian Y; Li Y; Jing Z; Fang W; Fang T; Li B; Chen Q; Lan T; Meng F; Zhang X; Liang X
ACS Synth Biol; 2024 Jun; 13(6):1679-1693. PubMed ID: 38819389
[TBL] [Abstract][Full Text] [Related]
11. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.
Shim KG; Zaidi S; Thompson J; Kottke T; Evgin L; Rajani KR; Schuelke M; Driscoll CB; Huff A; Pulido JS; Vile RG
Mol Ther; 2017 Apr; 25(4):962-975. PubMed ID: 28237836
[TBL] [Abstract][Full Text] [Related]
13. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.
Xu B; Yuan L; Gao Q; Yuan P; Zhao P; Yuan H; Fan H; Li T; Qin P; Han L; Fang W; Suo Z
Oncotarget; 2015 Aug; 6(24):20592-603. PubMed ID: 26008981
[TBL] [Abstract][Full Text] [Related]
14. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
15. Early transient suppression of immune checkpoint proteins T-cell immunoglobulin mucin-3 and programmed cell death-1 in peripheral blood lymphocytes after blastocyst transfer is associated with successful implantation.
Zhang T; Zhu W; Zhao Y; Cheung WC; Liu Y; Chen X; Du Y; Leung KT; Chan YL; Wang CC; Laird S; Li TC
Fertil Steril; 2020 Aug; 114(2):426-435. PubMed ID: 32199622
[TBL] [Abstract][Full Text] [Related]
16. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models.
Ma S; Tian Y; Peng J; Chen C; Peng X; Zhao F; Li Z; Li M; Zhao F; Sheng X; Zong R; Li Y; Zhang J; Yu M; Zhu Q; Tian X; Li Y; Neckenig MR; Liu H; Zhan P; Yue X; Wu Z; Gao L; Liang X; Liu X; Li C; Ma C
Sci Transl Med; 2023 Nov; 15(722):eadg6752. PubMed ID: 37967204
[TBL] [Abstract][Full Text] [Related]
17. Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1.
Hladíková K; Partlová S; Koucký V; Bouček J; Fonteneau JF; Zábrodský M; Tachezy R; Grega M; Špíšek R; Fialová A
Oral Oncol; 2018 Jul; 82():75-82. PubMed ID: 29909905
[TBL] [Abstract][Full Text] [Related]
18. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
19. Increased PD-1
Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
[TBL] [Abstract][Full Text] [Related]
20. TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells.
Cianciotti BC; Magnani ZI; Ugolini A; Camisa B; Merelli I; Vavassori V; Potenza A; Imparato A; Manfredi F; Abbati D; Perani L; Spinelli A; Shifrut E; Ciceri F; Vago L; Di Micco R; Naldini L; Genovese P; Ruggiero E; Bonini C
Front Immunol; 2024; 15():1315283. PubMed ID: 38510235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
